Eiropas Savienība - latviešu - EMA (European Medicines Agency)

janssen-cilag international nv - ciltacabtagene autoleucel - multiple mieloma - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

janssen-cilag international n.v. - teclistamab - multiple mieloma - antineoplastiski līdzekļi - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - antineoplastiski līdzekļi - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - belantamab mafodotin - multiple mieloma - antineoplastiski līdzekļi - blenrep is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

Latvija - latviešu - Zāļu valsts aģentūra

sanoswiss uab, lithuania - bikalutamīds - apvalkotā tablete - 50 mg

Latvija - latviešu - Zāļu valsts aģentūra

sanoswiss uab, lithuania - bikalutamīds - apvalkotā tablete - 150 mg

Latvija - latviešu - Zāļu valsts aģentūra

medac gesellschaft für klinische spezialpräparate mbh, germany - uz tuvās calmette-guérin (bcg) - pulveris un šķīdinātājs intravezikāli lietojamas suspensijas pagatavošanai

Latvija - latviešu - Zāļu valsts aģentūra

aj vaccines a/s, denmark - vakcīnas tuvās calmette-guérin (bcg) - pulveris un šķīdinātājs injekciju suspensijas pagatavošanai

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

3m health care limited - rivastigmine - alcheimera slimība - psychoanaleptics, , anticholinesterases - simptomātiska vieglas vai vidēji smaga alcheimera demences ārstēšana.

Latvija - latviešu - Zāļu valsts aģentūra

qp-services uk ltd, united kingdom - lidokaīns - krēms - 40 mg/g